aTyr Pharma Stock News

aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q4 2021 Results - Earnings Call Transcript

FDA End-of-Phase 2 meeting provides development pathway for efzofitimod (ATYR1923) in pulmonary sarcoidosis; planned registrational study to initiate in the third quarter of 2022.

aTyr Pharma (NASDAQ:LIFE) is scheduled to announce Q4 earnings results on Monday, March 14th, after market close.The consensus EPS Estimate is -$0.28 (+40.4% Y/Y) and the consensus…

After a meeting with the U.S. Food and Drug Administration ((FDA)), the clinical-stage biotech aTyr Pharma (LIFE) announced on Thursday that the company expected to initiate…

Regulatory path forward supports company’s intention to initiate a planned registrational study in the third quarter of 2022. Regulatory path forward supports company’s intention to initiate a pla

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological p

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is being held April 8 – 13, 2022, in New Orleans, LA, and virtually.

Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT

Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT

Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDT

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at two upcoming investor conferences in March.

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 5.41% and 4.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pa